Historically, EGFR inhibitors have not been effective against KRAS-mutant cancers; however, second generation inhibitors have shown promise in treating both KRAS- and EGFR-mutant tumors by targeting all members of the ErbB family of proteins (EGFR/ERbB1, HER2/ErbB2, HER3/ErbB3, HER4/ErbB4) [6]. This evidence concerns the gene ERBB4 and cancer.